financetom
Business
financetom
/
Business
/
Australia clears Chemist Warehouse-Sigma Healthcare $5.8 billion deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia clears Chemist Warehouse-Sigma Healthcare $5.8 billion deal
Nov 9, 2024 11:50 AM

(Reuters) - The Australian competition regulator, on Thursday, cleared privately owned pharmacy chain Chemist Warehouse's reverse takeover of Sigma Healthcare ( SIGGF ), paving the way to create an A$8.8 billion ($5.78 billion) entity after a year-long wait.

Sigma's stock surged almost 40%, the most on the Australian benchmark index, to hit a record high.

Chemist Warehouse had said roughly a year back it would buy Sigma for stock and A$700 million in cash, giving it a roughly 85% stake in the merged entity and a backdoor way to list on the stock exchange at a time when global capital markets were in the doldrums.

But the deal -- creating a company supplying around 1,000 Sigma-aligned pharmacies and owning 600 Chemist Warehouse outlets -- has been under the Australian Competition and Consumer Commission's (ACCC) scrutiny and was cleared after the companies made concessions to alleviate competition concerns.

The ACCC said the proposed deal was unlikely to substantially lessen competition subject to Sigma allowing franchises to opt out of their agreements without penalties to make it easier for a pharmacy to switch networks.

"The ACCC's analysis found that the proposed merger is unlikely to substantially lessen competition nationally or locally because other pharmacies and non-pharmacy retailers will continue to compete to the same extent they compete now," Chair Gina Cass-Gottlieb said.

Brokerage Jefferies said investors will get access to a standout retail franchise in the healthcare sector once the deal closes.

Despite the ACCC's clearance, the deal faces criticism from rival Ebos Australia and a powerful industry group in Canberra called Pharmacy Guild.

"The ACCC will need to carefully monitor the merger and its impact on patients," said a spokesperson for the Guild.

"Market consolidation in health services leads to non-competitive duopolies, an unequal distribution of doctors and a reduction in smaller businesses better equipped to provide local and personalised health services to their communities."

Ebos did not immediately respond to a Reuters request for comment. ($1 = 1.5129 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shell Boosts LNG Production Forecast As Refining Margins Surge
Shell Boosts LNG Production Forecast As Refining Margins Surge
Oct 7, 2025
Shell plc ( SHEL ) shares were trading higher premarket on Tuesday after the company revised its third-quarter outlook. The oil giant trimmed the guidance for production at Integrated Gas to around 910 and 950 thousand boe/d (versus the prior outlook of 910 – 970 thousand boe/d). The company expects Trading & Optimisation to be significantly higher than the second quarter of fiscal 2025...
IKEA buys US logistics tech firm Locus in online growth push
IKEA buys US logistics tech firm Locus in online growth push
Oct 7, 2025
LONDON/STOCKHOLM (Reuters) -IKEA has acquired U.S. logistics technology firm Locus, the two companies said on Tuesday, a deal the Swedish furniture retailer said would make its deliveries to shoppers smoother and faster as it invests to expand online sales. The takeover is in addition to a $2.2 billion push by Ingka Group, the biggest global IKEA franchisee, in the U.S....
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer
Oct 7, 2025
06:03 AM EDT, 10/07/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said in a regulatory filing Monday that it has appointed Cortney Caudill chief operating officer. Caudill most recently served at Aeglea Biotherapeutics as chief product officer before joining Halozyme in 2023, the company said. ...
Dyne Therapeutics Reports Strength, Function Improvement From Myotonic Dystrophy Drug Candidate in Ongoing Early Phase Trial
Dyne Therapeutics Reports Strength, Function Improvement From Myotonic Dystrophy Drug Candidate in Ongoing Early Phase Trial
Oct 7, 2025
06:03 AM EDT, 10/07/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Monday additional one-year data from its ongoing phase 1/2 trial of zeleciment basivarsen, or z-basivarsen, in patients with myotonic dystrophy type 1 demonstrated clinically meaningful improvements in strength and function using the selected registrational dose. New data include improvements in scores that measure upper limb function, strength...
Copyright 2023-2026 - www.financetom.com All Rights Reserved